Literature DB >> 17126214

Dosimetric validation of the MCNPX Monte Carlo simulation for radiobiologic studies of megavoltage grid radiotherapy.

Hualin Zhang1, Ellis L Johnson, Robert D Zwicker.   

Abstract

PURPOSE: To validate the MCNPX Monte Carlo simulation for radiobiologic studies of megavoltage grid radiotherapy. METHODS AND MATERIALS: EDR2 films, a scanning water phantom with microionization chamber and MCNPX Monte Carlo code, were used to study the dosimetric characteristics of a commercially available megavoltage grid therapy collimator. The measured dose profiles, ratios between maximum and minimum doses at 1.5 cm depth, and percentage depth dose curve were compared with those obtained in the simulations. The simulated two-dimensional dose profile and the linear-quadratic formalism of cell survival were used to calculate survival statistics of tumor and normal cells for the treatment of melanoma with a list of doses of the fractionated grid therapy.
RESULTS: A good agreement between the simulated and measured dose data was found. The therapeutic ratio based on normal cell survival has been defined and calculated for treating both the acute and late responding melanoma tumors. The grid therapy in this study was found to be advantageous for treating the acutely responding tumors, but not for late responding tumors.
CONCLUSIONS: Monte Carlo technique was demonstrated to be able to provide the dosimetric characteristics for grid therapy. The therapeutic ratio was dependent not only on the single alpha/beta value, but also on the individual alpha and beta values. Acutely responding tumors and radiosensitive normal tissues are more suitable for using the grid therapy.

Entities:  

Mesh:

Year:  2006        PMID: 17126214     DOI: 10.1016/j.ijrobp.2006.08.059

Source DB:  PubMed          Journal:  Int J Radiat Oncol Biol Phys        ISSN: 0360-3016            Impact factor:   7.038


  8 in total

1.  Tracing the earliest medical uses of high dose-per-fraction external beam radiation.

Authors:  Brian D Kavanagh
Journal:  J Radiosurg SBRT       Date:  2011

2.  The dosimetric enhancement of GRID profiles using an external collimator in pencil beam scanning proton therapy.

Authors:  Blake R Smith; Nicholas P Nelson; Theodore J Geoghegan; Kaustubh A Patwardhan; Patrick M Hill; Jen Yu; Alonso N Gutiérrez; Bryan G Allen; Daniel E Hyer
Journal:  Med Phys       Date:  2022-02-21       Impact factor: 4.071

3.  Physical aspects of a spatially fractionated radiotherapy technique for large soft tissue sarcomas.

Authors:  Egor Borzov; Raquel Bar-Deroma; Myroslav Lutsyk
Journal:  Phys Imaging Radiat Oncol       Date:  2022-05-04

4.  Grid Block Design Based on Monte Carlo Simulated Dosimetry, the Linear Quadratic and Hug-Kellerer Radiobiological Models.

Authors:  Somayeh Gholami; Hassan Ali Nedaie; Francesco Longo; Mohammad Reza Ay; Sharifeh A Dini; Ali S Meigooni
Journal:  J Med Phys       Date:  2017 Oct-Dec

5.  Biological Evaluation of Grid versus 3D Conformal Radiotherapy in Bulky Head and Neck Cancer.

Authors:  Najah Abdulmuneem Alanizy; Ehab Marouf Attalla; Ahmed Mosa Abdelaal; Mohamed Nabil Yassen; Medhat Wahba Shafaa
Journal:  J Med Phys       Date:  2022-08-05

6.  Is grid therapy useful for all tumors and every grid block design?

Authors:  Somayeh Gholami; Hassan Ali Nedaie; Francesco Longo; Mohammad Reza Ay; Stacey Wright; Ali S Meigooni
Journal:  J Appl Clin Med Phys       Date:  2016-03-08       Impact factor: 2.102

Review 7.  Radiobiological and Treatment-Related Aspects of Spatially Fractionated Radiotherapy.

Authors:  Leyla Moghaddasi; Paul Reid; Eva Bezak; Loredana G Marcu
Journal:  Int J Mol Sci       Date:  2022-03-20       Impact factor: 5.923

8.  A simple dosimetric approach to spatially fractionated GRID radiation therapy using the multileaf collimator for treatment of breast cancers in the prone position.

Authors:  Natasha L Murphy; Rino Philip; Matt Wozniak; Brian H Lee; Eric D Donnelly; Hualin Zhang
Journal:  J Appl Clin Med Phys       Date:  2020-10-29       Impact factor: 2.243

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.